Contravisory Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Contravisory Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,006	Closed	-$170K	–	415
2023 Q3	$170K	Buy	11,006 +705	+7%	+$10.9K	0.05%	204
2023 Q2	$162K	Buy	10,301 +3,999	+63%	+$65.5K	0.04%	208
2023 Q1	$104K	Buy	6,302 +591	+10%	+$9.41K	0.03%	216
2022 Q4	$89.1K	Sell	5,711 -11	-0.2%	-$154	0.02%	224
2022 Q3	$74K	Hold	5,722	–	–	0.02%	224
2022 Q2	$80K	Buy	+5,722	New	+$81.7K	0.03%	226
2020 Q4	–	Sell	-1,458	Closed	-$26K	–	275
2020 Q3	$26K	Hold	1,458	–	–	0.01%	212
2020 Q2	$28K	Sell	1,458 -86	-6%	-$1.54K	0.01%	210
2020 Q1	$23K	Buy	1,544 +77	+5%	+$1.4K	0.01%	231
2019 Q4	$29K	Sell	1,467 -17	-1%	-$325	0.01%	230
2019 Q3	$26K	Buy	1,484 +86	+6%	+$1.49K	0.01%	236
2019 Q2	$25K	Hold	1,398	–	–	0.01%	236
2019 Q1	$28K	Buy	+1,398	New	+$28.1K	0.01%	241

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Contravisory Investment Management's TAK Position: Q4 2023 in Review

Contravisory Investment Management sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 11,006 shares — an estimated $170K sold.

Contravisory Investment Management first reported a position in TAK in Q1 2019 and held it in 13 quarters. The position peaked at $170K in Q3 2023. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Contravisory Investment Management reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Contravisory Investment Management sold 11,006 Takeda Pharmaceutical shares in Q4 2023, an estimated $170K.
Contravisory Investment Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 13 quarters.
Contravisory Investment Management's Takeda Pharmaceutical position peaked at $170K in Q3 2023.
306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Contravisory Investment Management's 13F filing for Q4 2023, filed 11 Jan 2024.